Items tagged with Drug-resistant TB
South Africa scores new medicine worth millions – for free (post)
Drugmaker Otsuka Pharmaceutical won’t charge South Africa for using its new tuberculosis (TB) drug in a pilot programme, but South Africa’s free deal is unlikely to last.
Biological version of malware reverses antibiotic resistance in TB (post)
As the mycobacterium that causes tuberculosis has frighteningly become resistant to one drug after another, scientists for years have searched for new compounds that will stop the pathogen before it kills. Now, in a novel twist, researchers have found a way to recruit help from none other than Mycobacterium tuberculosis itself to make the deadly pathogen susceptible to an existing tuberculosis (TB) drug that it has learned to dodge.
Mumbai hospital to screen 6,000 TB patients (post)
PD Hinduja National Hospital and Medical Research Centre has been chosen as the country’s nodal center for a global genome study of 1 lakh TB patients to examine bacterial resistance in them. India will screen at least 6,000 patients during the course of the four-year study.
Despite 2 ‘miracle’ drugs, TB patient dies after long battle (post)
A 19-year-old tuberculosis (TB) patient who was among the first in India to receive both Bedaquiline and Delamanid drugs died last month after battling the infection for a prolonged period. In her final days, she was on oxygen support after doctors labelled her as “therapeutically incurable”.
DR-TB STAT on WHO bedaquiline recommendations (post)
The DR-TB Scale-Up Treatment Action Team (DR-TB STAT) issued a Bedaquiline Bulletin.
Sequella and Infectex announce results of clinical trial with SQ109 (post)
Sequella and Infectex announced positive results of a Phase 2b-3 clinical study of SQ109 added to the standard drug therapy regimen in patients with multidrug-resistant pulmonary TB (MDR-TB). SQ109 is a new small molecule drug discovered by scientists at Sequella and the US National Institutes of Health.
Global rise of multidrug-resistant TB threatens to derail decades of progress (post)
New antibiotics are becoming available for the first time but without accurate diagnostics, clear treatment guidelines, and improved control efforts, their effectiveness could be rapidly lost.
Antibiotic research priorities: ready, set, now go (post)
When faced with a medical emergency and limited resources, triage is essential. Deciding where needs are greatest helps to focus attention and provoke action, in line with a utilitarian aim of maximising gains and minimising harms for the greatest number of people. The importance of setting priorities applies equally to a global emergency as to a local one. With the threat of antimicrobial resistance now recognised at the highest political levels, WHO has compiled a list of pathogens on which research and development of new antimicrobials should be focused.
FATE: the new partnership to Fight Against TB in Central and Eastern Europe (post)
Central and Eastern Europe is a hotspot for drug-resistant TB and most countries in the region face similar threats and opportunities.
Regardless of the WHO snafu, TB should be a priority in the global AMR response (post)
On 27 February, the WHO published a list of antibiotic-resistant "priority pathogens." The first of its kind, this list is intended to promote research, discovery and development (R&D) of new antibiotics, as part of WHO’s efforts to address the threat of antimicrobial resistance (AMR) and respond to an urgent public health need. The hope is that the list will catalyse governments to incentivize basic science and advanced R&D.
Page 40 of 117 · Total posts: 0
←First 39 40 41 Last→